Education
About Us
Working with TipRanks
Follow Us
PBE ETF Price & Analysis
PBE ETF Chart & Stats
Day’s Range― - ―
52-Week Range$54.52 - $72.84
Previous Close$66.91
VolumeN/A
Average Volume (3M)5.88K
AUM233.59M
NAV66.15
Expense Ratio0.58%
Holdings Count32
Beta0.85
Inception DateJun 23, 2005
Next Dividend Ex-DateN/A
Dividend Yield
(0.79%)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume4,788
30 Day Avg. Volume5,878
AlphaN/A
ETF Overview
Invesco Dynamic Biotechnology & Genome ETF
The Invesco Dynamic Biotechnology & Genome ETF (PBE) is a specialized exchange-traded fund that offers investors a targeted opportunity to engage with the cutting-edge biotechnology sector within the broader health care industry. This ETF is meticulously designed to capture the growth potential of companies at the forefront of biotechnological innovation and genomic research, an area that is transforming the future of medicine and therapeutics. By investing in PBE, stakeholders gain exposure to a dynamic portfolio of firms that are pioneering advancements in genetic engineering, molecular biology, and biopharmaceutical development. With a focus on both established leaders and emerging innovators in the biotechnology niche, PBE provides a balanced approach to tapping into the sector's rapid growth and scientific breakthroughs. Ideal for those looking to leverage sector-specific growth trends, this ETF stands out for its strategic emphasis on companies that are shaping the future of healthcare solutions, making it a compelling choice for forward-thinking investors.
Invesco Dynamic Biotechnology & Genome ETF (PBE) Fund Flow Chart
Invesco Dynamic Biotechnology & Genome ETF (PBE) 1 year Net Flows: -$31M
PBE ETF News
PBE ETF FAQ
What was PBE’s price range in the past 12 months?
PBE lowest ETF price was $54.52 and its highest was $72.84 in the past 12 months.
What is the AUM of PBE?
As of Jul 11, 2025 The AUM of PBE is 233.59M.
Is PBE overvalued?
According to Wall Street analysts PBE’s price is currently Undervalued.
Does PBE pay dividends?
PBE does not currently pay dividends.
How many shares outstanding does PBE have?
Currently, no data Available
Which hedge fund is a major shareholder of PBE?
Currently, no hedge funds are holding shares in PBE
PBE ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Illumina
5.57%
Royalty Pharma PLC
5.17%
Alnylam Pharmaceuticals
5.08%
Amgen Inc
4.96%
Vertex Pharmaceuticals Inc.
4.94%
Gilead Sciences
4.79%
Biomarin Pharmaceutical Inc.
4.68%
United Therapeutics Corp.
4.41%
Anavex Life Sciences
3.96%
Blueprint Medicines Corp.
3.29%
Total46.86%
See All Holdings